Acceleron (XLRN) option implied volatility flat into Phase III Believe results

Acceleron Pharma (NASDAQ: XLRN) July call option implied volatility is at 62, August is at 56; compared to its 52-week range of 37 to 152 into announcing with its partner Celgene (CELG) positive Phase III Believe results for luspatercept in transfusion dependent beta thalassemia.

You May Also Be Interested In

• SpaceX (SPCX) call put ratio 2 calls to 1 put as share price at $160
• Qualcomm (QCOM) spreader of July 2 weekly 212.50 and July 10 weekly 192.50 calls
• CNH Industrial (CNH) 3800 contracts of August 12.50 calls trade, share price down 2%